Sunday, Sep 20, 2020 | Last Update : 05:33 PM IST

180th Day Of Lockdown

Maharashtra118801585793332216 Andhra Pradesh6177765307115302 Tamil Nadu5364774812738751 Karnataka5113454048417922 Uttar Pradesh3362942632884771 Delhi2347011981034877 West Bengal2155801870614183 Telangana1713061397001033 Odisha167161133466722 Bihar164224149722855 Assam150349121610528 Kerala12221687341490 Gujarat119088999083271 Rajasthan109088906851293 Haryana103773816901069 Madhya Pradesh97906743981877 Punjab90032658182646 Chhatisgarh7777541111628 Jharkhand6710052807590 Jammu and Kashmir5971138521951 Uttarakhand3713924810460 Goa2678320844327 Puducherry2142816253431 Tripura2069612956222 Himachal Pradesh11190691997 Chandigarh92566062106 Manipur8430653951 Arunachal Pradesh6851496713 Nagaland5306407910 Meghalaya4356234232 Sikkim2119178923 Mizoram15069490
  Science   31 Mar 2020  Human trials of Johnson & Johnson coronavirus vaccine to begin in September

Human trials of Johnson & Johnson coronavirus vaccine to begin in September

AFP
Published : Mar 31, 2020, 6:02 pm IST
Updated : Mar 31, 2020, 6:02 pm IST

US pharmaceutical Moderna has already moved into human trials for its vaccine candidate, as has China's CanSinoBIO.

Representative image of a vaccine being administered to a person. (Photo | US Air Force - Briana Jones)
 Representative image of a vaccine being administered to a person. (Photo | US Air Force - Briana Jones)

Washington: Johnson & Johnson has said it had selected a lead candidate vaccine for the new coronavirus that would move to human trials by September and could be ready for emergency use by early next year.

The pharmaceutical company has signed an agreement with the US government's Biomedical Advanced Research and Development Authority to invest USD 1 billion in the effort, it said in a statement on Monday.

 

J&J began working on the vaccine under investigation - Ad26 SARS-CoV-2 - in January using the same technology it used to develop a candidate vaccine for Ebola.

Paul Stoffels, the company's chief scientific officer, told AFP his team had combined a common cold virus incapable of replicating with parts of the coronavirus, and hoped it would trigger a human immune response.

"We had several vaccine candidates which we tested in animals in order to choose the best one, that took 12 weeks, from January 15 to today," he said.

They also had to evaluate which candidate vaccine could be upscaled, "to make sure on the one hand it works, and on the other hand, we can make a lot of it," he added.

 

Though there has never before been a successful human vaccine for any virus belonging to the coronavirus family, Stoffels said he was confident of achieving this milestone because J&J was working with the same team that had developed a candidate vaccine for SARS, which killed almost 800 people between 2002-2003.

The team's work was discontinued once the SARS outbreak was brought under control and interest was lost in bringing the vaccine to market.

"The question is, can you protect for infection or can you protect for severe disease? In many diseases, like in influenza, when you vaccinate on an annual basis, you protect for severe disease, you don't always protect for infection," said Stoffels.

 

J&J would also need to determine that the vaccine doesn't backfire and give people a higher chance of getting the disease.

The company said it was expanding its global manufacturing capacity both in the US and in other countries, to help it supply more than a billion doses of its vaccine around the world.

J&J is also working on antiviral treatments against the coronavirus.

Separately, the US pharmaceutical Moderna has already moved into human trials for its vaccine candidate, as has China's CanSinoBIO.

There are currently no approved vaccines or treatments for the disease.

Tags: coronavirus (covid-19), coronavirus vaccine, human trials, johnson & johnson, sars-cov-2, ebola